COMPANY:

Canhelp Genomics

"From September 7 to 11, 2024, the 36th European Congress of Pathology (ECP 2024) was held at the iconic conference center, Fortezza da Basso, in Florence, Italy. As a premier event in the field of pathology in Europe and worldwide, ECP 2024 attracted more than 6,000 experts, scholars, and industry professionals from around the globe...At the congress, Canhelp Genomics presented our latest flagship products, including Canhelp-Origin and Canhelp-UriBLAD, enable precise molecular profiling that supports accurate diagnosis and personalized treatment planning for cancer patients."

"The collaborative efforts between Professor Yao Yu's research group from the Department of Neurosurgery, Professor Xiong Ji's team from the Department of Pathology at Huashan Hospital, Shanghai Medical College, Fudan University, and the R&D team of Canhelp Genomics have resulted in the publication of 'Development and validation of a 23-gene expression signature for molecular subtyping of Medulloblastoma (MB) in a long-term Chinese cohort'...The Canhelp®-MB Assay, resulting from this collaboration, marks a significant advancement in the molecular subtyping of MB utilizing gene expression profiling."

"...the Kebang Gene R&D team jointly published a paper in 'European Urology Oncology' (IF=8.2) published the research results titled 'Large-scale Prospective Validation Study of a Multiplex RNA Urine Test for Noninvasive Detection of Upper Tract Urothelial Carcinoma' in the journal . This study conducted a prospective multi-center clinical trial and confirmed that the urothelial cancer gene detection method (Canhelp ® -UriBLAD Assay) based on gene expression profiles can effectively identify upper urinary tract urothelial cancer and other urinary system diseases. The overall sensitivity was 90.16% and the specificity was 88.89%." "

"In 2023, in order to accelerate the high-quality development of the biomedical industry, Hangzhou City will conduct selection activities in accordance with the relevant requirements of the 'Notice on Organizing the Application for the Recommended Catalog of Innovative and High-quality Hangzhou-made Pharmaceutical Devices'. After the stages of enterprise declaration, district and county preliminary review, and expert review, two products of Canbang Gene Tumor Tissue Origin Gene Detection Kit (PCR Fluorescent Probe Method) and Tumor Tissue Origin Gene Analysis Software were selected as 'Hangzhou Innovative High-quality Hangzhou-made Pharmaceutical Devices' Recommended directory."

"Recently, the bladder cancer mRNA detection technology (UriBLAD ® mRNA Test) independently developed by Canbang Gene was authorized by the United States Patent and Trademark Office (USPTO) for an invention patent (patent number: US11401560B2). The invention discloses a group of genes and related kits for non-invasive detection of bladder cancer, provides a method for non-invasive detection of bladder cancer in urine samples, and can be used for early diagnosis and recurrence monitoring of bladder cancer."

"Chinese molecular diagnostics company Canhelp Genomics has received approval from China's National Medical Products Administration (NMPA) for its Canhelp-Origin pan-cancer test and companion analysis software...A PCR-based tissue-of-origin assay, the Canhelp-Origin Test can measure the gene expression pattern of 90 specific markers of tissue samples and classifies 21 major tumor types that cover more than 95 percent of solid tumors by incidence, the company said."

"Hangzhou Kebang Gene Technology Co., Ltd. (hereinafter referred to as "Kebang Gene") independently developed the tumor tissue origin gene detection kit (PCR fluorescent probe method) and the tumor tissue origin gene analysis software (hereinafter collectively referred to as "tumor tissue origin") . Genetic testing”) passed the review of the National Medical Products Administration (NMPA), and was officially approved the third-class medical device registration certificate (National Instruments Approval 20223400901, National Instruments Approval 20223210928)."